

**REMARKS**

Claims 1, 4-18, 84, and 97-154 were pending in the application. By this amendment, claims 104 and 106 are amended. New claims 155-225 are added. Upon entry of this amendment, claims 1, 4-18, 84, and 97-225 are pending.

New claims 155-208 and 210-214, all of which directly or indirectly depend from previously presented claims, further recite specific pharmaceutical agents. Support for these new claims can be found, for example, on page 4, line 30 to page 5, line 11 of the specification. New claims 209 and 215-218, all of which depend from previously presented claims, further specify that the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles. Support for these claims can be found, for example, page 11, lines 17-18 and 30-33 of the specification. New claims 219-225, all of which depend from previously pending claims, further specify that the albumin is human serum albumin. Support for these claims can be found, for example, on page 14, lines 8-9 of the specification. No new matter has been added.

With respect to claim amendments and cancellation, Applicants have not dedicated or abandoned any unclaimed subject matter and moreover have not acquiesced to any rejections and/or objections made by the Patent Office. Applicants expressly reserve the right to pursue prosecution of any presently excluded subject matter or claim embodiments in one or more future continuation and/or divisional application(s).

**CONCLUSION**

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **420052000300**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 23, 2007

Respectfully submitted,

By   
Jian Xiao

Registration No.: 55,748 for  
Catherine Polizzi

Registration No.: 40,130  
MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
(650) 813-5736